2025 Outlook

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

The Q3 closing will add Blueprint’s FDA-approved systemic mastocytosis therapy Ayvakit alongside late-stage candidates to Sanofi’s portfolio.